| WYETH HOLDINGS CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120034261 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 02-09-2012 |
| 20110151546 | GLYCOPEPTIDE ANTIBIOTICS - The invention provides compounds of formula | 06-23-2011 |
| 20110076299 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 03-31-2011 |
| 20100233117 | Adjuvant combination formulations - The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen. | 09-16-2010 |
| 20100221288 | NOVEL STREPTOCOCCUS PNEUMONIAE OPEN READING FRAMES ENCODING POLYPEPTIDE ANTIGENS AND USES THEREOF - The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of | 09-02-2010 |
| 20100022593 | Process for Producing Anticancer Agent LL-D45042 - The disclosure describes the production of anticancer agent LL-D45042, having the structure: | 01-28-2010 |
| 20090239261 | ASSEMBLY OF WILD-TYPE AND CHIMERIC INFLUENZA VIRUS-LIKE PARTICLES (VLPs) - Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs. | 09-24-2009 |
| 20090209452 | SUBSTANTIALLY PURE GLYCOPEPTIDE ANTIBIOTICS AC-98-1; AC-98-2; AC-98-3; AC-98-4 AND AC-98-5 - The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism | 08-20-2009 |
| 20090176720 | COMPOSITIONS CONTAINING PIPERACILLIN AND TAZOBACTAM USEFUL FOR INJECTION - An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution. | 07-09-2009 |
| 20090148465 | MUTANTS OF THE P4 PROTEIN OF NONTYPABLE HAEMOPHILUS INFLUENZAE WITH REDUCED ENZYMATIC ACTIVITY - A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable | 06-11-2009 |
| 20090075839 | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigents and uses thereof - The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of | 03-19-2009 |
| 20080311144 | MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT - Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule. | 12-18-2008 |
| 20080255157 | 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents - This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. | 10-16-2008 |
| 20080221181 | COMPOUNDS FOR TREATING TUMORS - The invention provides compounds of formula (I): | 09-11-2008 |
| 20080213303 | MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT - Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule. | 09-04-2008 |
